Burleson & Co’s Vir Biotechnology VIR Stock Holding History

Burleson & Co’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-10	Closed	-$1K	–	405
2021 Q1	$1K	Buy	+10	New	+$539	﹤0.01%	353

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

APF

Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Burleson & Co's VIR Position: Q2 2021 in Review

Burleson & Co sold out of Vir Biotechnology (VIR) in Q2 2021, closing a stake of 10 shares — an estimated $1K sold.

Burleson & Co first reported a position in VIR in Q1 2021 and held it in 1 quarter. The position peaked at $1K in Q1 2021. 166 funds tracked by Wall St. Rank hold VIR as of Q2 2021.

Burleson & Co reported no remaining Vir Biotechnology position as of Q2 2021 after selling out during the quarter.
Burleson & Co sold 10 Vir Biotechnology shares in Q2 2021, an estimated $1K.
Burleson & Co first reported a position in Vir Biotechnology in Q1 2021 and held it in 1 quarter.
Burleson & Co's Vir Biotechnology position peaked at $1K in Q1 2021.
166 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2021.

Based on Burleson & Co's 13F filing for Q2 2021, filed 22 Jul 2021.